Moderna has been scaling up to meet the promise of mRNA science since the new generation of therapeutics and vaccines were first discovered. So when COVID-19 swept across the globe, they were one of the first to develop a vaccine. But with early clinical success came the need to pivot.
Moderna’s mRNA technology was fast-tracked for commercialization by 2 - 3 years. This meant they had to rapidly scale up their commercial and medical leadership teams in order to deliver.
Since then, Stevenson has partnered with Moderna to quickly place dozens of executives. These successful appointments will help lead them through the pandemic and set the platform for their long-term growth.